US/UK/Canada

Share

Contacts

  • Morten Henneveld

    CEO


    +46 18 55 39 93

    • Links

    Pick a time period -
    Tags ( Active)

    New scientific paper shows OssDsign Cranial PSI results with zero implant-related complications and positive treatment outcomes in largest US case series to date

    Uppsala, Sweden, September 26, 2022. OssDsign AB (publ.) today announces that an independent clinical research team in New York, U.S., lead by Ralph Rahme, M.D., F.A.C.S., has published their clinical findings, describing treatment outcomes with OssDsign PSI in the largest U.S. cohort to date. The study included 18 patients who underwent cranioplasty, showing that the procedure was successful in all cases, and that no implant-related complications occurred during a 6-month median follow-up period. The clinical paper is published in the journal World Neurosurgery.OssDsign Cranial PSI is a

    OssDsign launches Cranial PSI in Japan and records first sales

    Uppsala, June 21, 2022. OssDsign AB (publ.) today announces that the company has completed its first sales of OssDsign Cranial PSI in Japan. The launch marks an important strategic milestone, following a period of postponed commercial activities due to the Covid-19 pandemic.OssDsign Cranial PSI is a patient-specific cranial implant made from 3D printed medical-grade titanium covered by a regenerative calcium phosphate composition. While the titanium skeleton reinforces the implant and resists physical and mechanical stress, the unique calcium phosphate composition provides healing and

    OssDsign announces that SEB has initiated research coverage of the company

    Uppsala, June 8, 2022. OssDsign AB (publ.) today announces that Skandinaviska Enskilda Banken (publ) (SEB) has been engaged to produce regular corporate research reports on the company. The intention is to raise the visibility of OssDsign in the capital market and enable investors as well as other stakeholders to develop an improved understanding of its business."We are glad to announce that SEB, one of the most well-renowned financial institutions in the Nordics, has initiated corporate research coverage in OssDsign. This will further increase our visibility in the financial community,"

    OssDsign announces the establishment of a U.S. Strategic Surgeon Advisory Board

    Uppsala, June 7, 2022. OssDsign AB (publ.) today announces that the company has established a Strategic Surgeon Advisory Board (SSAB) in the U.S. The primary objective of the SSAB is to assist the company with guidance and advice on strategic matters.The SSAB will consist of seven leading U.S. neurosurgical and orthopaedic spinal surgeons who will advise the company on matters related to the future direction and priorities for the company such as new product development, regulatory pathways, clinical programs and similar areas that carry strategic importance. OssDsign’s SSAB will

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media